Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This ...

Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor.

This country research report on Vietnam Primary Cell Culture Market offers comprehensive insights into the market landscape, customer intelligence, and competitive strategies in the Vietnam market.

Validation of lymphocyte to monocyte ratio in resected small bowel adenocarcinoma as a predictor of survival. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does ...